Crinetics Pharmaceuticals, Inc.: FARALLON CAPITAL MANAGEMENT, L.L.C. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Farallon Capital Management amended its Schedule 13G filing on Crinetics Pharmaceuticals, disclosing a change in its passive stake in the company. The filing, accession number 0000908834-26-000520, updates the hedge fund's previously reported position in the clinical-stage biopharmaceutical firm. The amendment signals a shift in Farallon's holdings, though the filing did not specify the exact size or direction of the change in the headline disclosure. Investors watch 13G amendments for clues about institutional conviction in Crinetics, whose shares trade on the Nasdaq. What to watch next: the full filing details on Farallon's revised share count and percentage ownership.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Farallon Capital Management, L.L.C., Crinetics Pharmaceuticals, Inc.